BMS 310705

Drug Profile

BMS 310705

Alternative Names: BMS310705

Latest Information Update: 13 Oct 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb; GBF
  • Developer Bristol-Myers Squibb; Helmholtz Centre for Infection Research GmbH
  • Class Antineoplastics; Epothilones; Macrolides
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Aug 2005 A preclinical study has been added to the pharmacokinetics section
  • 05 Nov 2003 A study has been added to the adverse events and Cancer therapeutic trials sections
  • 04 Jul 2003 Data presented at the 39th Annual Meeting of the Society of Clinical Oncology (ASCO-2003) have been added to the adverse events, pharmacokinetics, Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top